Genetron Health to Announce Fourth Quarter and Full Year 2020 Unaudited Financial Results and Host Investor Call on March 25, 2021

Genetron Health to Announce Fourth Quarter and Full Year 2020 Unaudited Financial Results and Host Investor Call on March 25, 2021




Genetron Health to Announce Fourth Quarter and Full Year 2020 Unaudited Financial Results and Host Investor Call on March 25, 2021

BEIJING–(BUSINESS WIRE)–Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it will report unaudited financial results for the fourth quarter and full year ended December 31, 2020 on March 25, 2021 before the US market open.

Management will host a conference call for investors at 8:30 a.m. ET (8:30 p.m. Beijing time) on Thursday, March 25, 2021. The conference call can be accessed by dialing the following numbers:

United States:

 

+1-845-675-0437

China Domestic:

 

400-620-8038

Hong Kong:

 

+852-3018-6771

International:

 

+65-6713-5090

Conference ID:

 

5379298

Participants are encouraged to dial into the call at least 15 minutes in advance due to high call volumes.

A replay will be accessible through April 2, 2021 by dialing the following numbers:

Telco replay number

United States:

 

+1-855-452-5696

International:

 

+61-2-8199-0299

Conference ID:

 

5379298

A simultaneous webcast of the conference call will be available on the “News and Events” page of the Investors section of the Company’s website. A replay of the webcast will be available for 30 days following the event. For more information, please visit ir.genetronhealth.com.

About Genetron Holdings Limited

Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq:GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit ir.genetronhealth.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as “may”, “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

Contacts

Investor Relations Contact
US:
Hoki Luk

Head of Investor Relations

Email: hluk@genetronhealth.us
Phone: +1 (408) 891-9255

David Deuchler, CFA

Managing Director | Gilmartin Group

Email: David@gilmartinir.com
Phone: (917) 209-5605